← 홈

고형암 (전체)

911개 · ADC 1068 · Antibody 5456 · CGT 2744 · 다음 갱신 D-12 · 마지막 7월 13일

인기최근 업데이트큐레이션임상 많은갱신 필요ORR최신Phase 3FDA승인프로그램 911개
ADCBiologicstaleMerck Sharp & Dohme LLCPhase 2

Docetetaxel (Docetetaxel)

Carcinoma, Non-Small-Cell Lung · Carcinoma, Non-Small-Cell Lung

#CarcinomaNon-Small-CellLung#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+3
임상시험 1상태 RECRUITING
AntibodystaleNektar TherapeuticsPhase 2

nivolumab (Opdivo, Dose Escalation Doublet: Combination of NKTR-214 + nivolumab)

Melanoma; Renal Cell Carcinoma · HER2

#HER2#Antibody#Phase2#항체#면역항체+4
효능 ORR 64%임상시험 1상태 ACTIVE
AntibodystaleUniversity of Colorado, DenverPhase 1

durvalumab (Imfinzi, Dose Escalation of Durvalumab and Trabectedin)

Solid Tumor, Adult · Solid Tumor, Adult

#SolidTumorAdult#Antibody#Phase1#항체#면역항체+4
임상시험 1상태 DISCONTINUED
AntibodystaleNektar TherapeuticsPhase 2

nivolumab (Opdivo, Dose Expansion Doublet: Combination of NKTR-214 + nivolumab)

Melanoma; Renal Cell Carcinoma · HER2

#HER2#Antibody#Phase2#항체#면역항체+4
효능 ORR 64%임상시험 1상태 ACTIVE
AntibodystaleNektar TherapeuticsPhase 2

nivolumab (Opdivo, Dose Expansion Triplet: Combination of NKTR-214+ nivolumab+ ipilimumab)

Melanoma; Renal Cell Carcinoma · HER2

#HER2#Antibody#Phase2#항체#면역항체+4
효능 ORR 64%임상시험 1상태 ACTIVE
AntibodystaleUniversity of Colorado, DenverPhase 1

durvalumab (Imfinzi, Dose Expansion of Durvalumab and Trabectedin)

Solid Tumor, Adult · Solid Tumor, Adult

#SolidTumorAdult#Antibody#Phase1#항체#면역항체+4
임상시험 1상태 DISCONTINUED
AntibodystaleTesaro, Inc.Phase 3

TSR-042 (Dostarlimab, Dostarlimab (TSR-042))

Ovarian Neoplasms; Ovarian, Fallopian Tube and Primary Peritoneal Carcinoma · Ovarian Neoplasms

#OvarianNeoplasms#Antibody#Phase3#항체#면역항체+4
효능 ORR 88%임상시험 1상태 RECRUITING
AntibodystaleAkesoPhase 2

Drug: AK129 Drug：cadonilimab Drug：oxaliplatin Drug：capecitabine (Drug: AK129 Drug：cadonilimab Drug：oxaliplatin Drug：capecitabine)

Gastric Adenocarcinoma; Gastroesophageal Junction Adenocarcinoma · Gastric Adenocarcinoma

#GastricAdenocarcinoma#Antibody#Phase2#항체#면역항체+3
임상시험 1상태 RECRUITING
ADCBiologicstaleInnovent Biopharmaceutical Tech…Phase 1

Drug: IBI3028 (Drug: IBI3028)

Solid Tumor; Colorectal Cancer · Solid Tumor

#SolidTumor#ADC#Phase1#항체약물접합체#antibody-drug-conjugate+2
임상시험 1상태 RECRUITING
AntibodystaleSichuan Kelun-Biotech Biopharma…Phase 1

Drug: Tagitanlimab Drug: Capecitabine (Drug: Tagitanlimab Drug: Capecitabine)

Advanced Solid Tumors · Advanced Solid Tumors

#AdvancedSolidTumors#Antibody#Phase1#항체#면역항체+2
임상시험 1상태 RECRUITING
AntibodystaleEli LillyPhase 2

Drug: Tislelizumab, Cetuximab, Cisplatin and Nab-paclitaxel (Drug: Tislelizumab, Cetuximab, Cisplatin and Nab-paclitaxel)

Oral Squamous Cell Carcinoma (OSCC); Oropharyngeal Squamous Cell Carcinoma (SCC) · Oral Squamous Cell Carcinoma (OSCC)

#OralSquamousCellCarcinomaOSCC#Antibody#Phase2#항체#면역항체+3
임상시험 1상태 RECRUITING
CGTBiologicstaleBeijing BiotechPhase 2

Dual-target CAR-NK cell product (Dual-target CAR-NK cell product)

Epithelial Ovarian Cancer; Primary Peritoneal Carcinoma · FRα

#FR#CGT#Phase2#세포유전치료#CAR-T+4
임상시험 1상태 RECRUITING
CGTBiologicstaleSichuan UniversityPhase 1

Dual-targeting CLDN18.2 and PD-L1 CAR-T cells (Dual-targeting CLDN18.2 and PD-L1 CAR-T cells)

Advanced Solid Tumor · PD-L1

#PD-L1#CGT#Phase1#세포유전치료#CAR-T+3
임상시험 1상태 RECRUITING
CGTBiologicstaleSichuan UniversityPhase 1

Dual-targeting HER2 and PD-L1 CAR-T cells (Dual-targeting HER2 and PD-L1 CAR-T cells)

Peritoneal Carcinoma Metastatic; Pleural Effusion, Malignant · HER2

#HER2#CGT#Phase1#세포유전치료#CAR-T+5
임상시험 1상태 RECRUITING
AntibodystaleCelgenePhase 2

Duravalumab (Duravalumab)

Carcinoma, Non-Small-Cell Lung · Carcinoma, Non-Small-Cell Lung

#CarcinomaNon-Small-CellLung#Antibody#Phase2#항체#면역항체+4
임상시험 1상태 ACTIVE
AntibodystaleAstraZenecaPhase 2

Cohort 1-3 (Durvalumab, Durvalumab (Cohort 1-3))

Urothelial Carcinoma; Bladder Cancer · Urothelial Carcinoma

#UrothelialCarcinoma#Antibody#Phase2#항체#면역항체+3
임상시험 1상태 RECRUITING
AntibodystaleAstraZenecaPhase 2

Cohort 4/5 (Durvalumab, Durvalumab (Cohort 4/5))

Urothelial Carcinoma; Bladder Cancer · Urothelial Carcinoma

#UrothelialCarcinoma#Antibody#Phase2#항체#면역항체+3
임상시험 1상태 RECRUITING
AntibodystaleAstraZenecaPhase 2

durvalumab (Imfinzi, Durvalumab (Imfinzi) immunotherapy)

Hepatocellular Carcinoma · Hepatocellular Carcinoma

#HepatocellularCarcinoma#Antibody#Phase2#항체#면역항체+2
임상시험 1상태 RECRUITING
AntibodystaleAstraZenecaPhase 2

for the first 8, 21-day, cycles (Durvalumab, Durvalumab (for the first 8, 21-day, cycles))

Locally Advanced, Unresectable or Metastatic Cholangiocarcinoma With an IDH1 Mutation · Locally Advanced, Unresectable or Metast

#LocallyAdvancedUnresectableorMet#Antibody#Phase2#항체#면역항체+4
임상시험 1상태 RECRUITING
AntibodystaleAstraZenecaPhase 2

starting from cycle 9 (Durvalumab, Durvalumab (starting from cycle 9))

Locally Advanced, Unresectable or Metastatic Cholangiocarcinoma With an IDH1 Mutation · Locally Advanced, Unresectable or Metast

#LocallyAdvancedUnresectableorMet#Antibody#Phase2#항체#면역항체+4
임상시험 1상태 RECRUITING

27 / 46 페이지

← 이전다음 →